Shikonin Mediates Apoptosis Through G Protein-Coupled Estrogen Receptor of Ovarian Cancer Cells

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2022 Oct 17

PMID 36248433

Authors

Xinyue Liu

Yao Yang

Xuefei Tang

Li Guo

Xinhui Tang

Ting Zhu

Tiannan Zhao

Weina Zhang

Ping Zhang

Affiliations

Soon will be listed here.

Abstract

This study was intended to establish the predictive target of Shikonin (SK) against ovarian cancer using network pharmacology and to clarify the potential mechanism of SK in promoting apoptosis in ovarian cancer. Cell Counting Kit-8 assay, plate clone assays, LDH assay, flow cytometric analysis of Annexin V-fluorescein isothiocyanate/propidium iodide staining, and western blotting were used to assess the effect of SK on apoptosis of ovarian cancer cell lines (SKOV3 and A2780). Pharmacodynamic targets were used to predict the targets of SK and ovarian cancer. Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway enrichment analyses were used to analyze the biological functions and signal pathways of these targets. SK promoted apoptosis in ovarian epithelioid adenocarcinoma cells. SK-ovarian cancer pharmacodynamic target analysis screened 17 related genes. GO and KEGG analyses showed that SK affected the estrogen signaling pathway. SK inhibited the expression of GPER in SKOV3 and A2780 cells and downregulated the expression of EGFR, p-EGFR, PI3K, and -AKT in a concentration-dependent manner. The apoptosis-promoting effect of SK was enhanced by GPER-specific agonist G1 and inhibited by the specific inhibitor G15. The expression of EGFR, -EGFR, PI3K, and -AKT was decreased by G1 and reversed by G15. SK also inhibited tumor growth in the SKOV3 xenograft model, and it acted synergistically with G1. However, the effect can be attenuated by G15 in vivo. In summary, SK may affect the apoptosis of ovarian cancer cells through GPER/EGFR/PI3K/AKT, and GPER may be a key target of SK in ovarian cancer cell apoptosis.

Citing Articles

Shikonin reduces M2 macrophage population in ovarian cancer by repressing exosome production and the exosomal galectin 3-mediated β-catenin activation.

Wang M, Sun Y, Gu R, Tang Y, Han G, Zhao S J Ovarian Res. 2024; 17(1):101.

PMID: 38745186 PMC: 11092256. DOI: 10.1186/s13048-024-01430-3.

Shikonin Suppresses Cell Tumorigenesis in Gastric Cancer Associated with the Inhibition of c-Myc and Yap-1.

Zhang F, Chu M, Liu J, Zhao Q, Zhu Y, Wu X Comb Chem High Throughput Screen. 2023; 27(13):1919-1929.

PMID: 37957853 DOI: 10.2174/0113862073254088231020082912.

Role of Estrogen Receptor β, G-Protein Coupled Estrogen Receptor and Estrogen-Related Receptors in Endometrial and Ovarian Cancer.

Schuler-Toprak S, Skrzypczak M, Grundker C, Ortmann O, Treeck O Cancers (Basel). 2023; 15(10).

PMID: 37345182 PMC: 10216512. DOI: 10.3390/cancers15102845.

References

Hao Z, Qian J, Yang J . Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK. Oncol Lett. 2015; 9(2):629-633. PMC: 4301518. DOI: 10.3892/ol.2014.2771. View

Filardo E, Thomas P . GPR30: a seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab. 2005; 16(8):362-7. DOI: 10.1016/j.tem.2005.08.005. View

Yu T, Cheng H, Ding Z, Wang Z, Zhou L, Zhao P . GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells. Mol Cell Endocrinol. 2020; 506:110762. DOI: 10.1016/j.mce.2020.110762. View

Lin H, Han H, Wang Y, He D, Sun W, Feng L . Shikonin and 4-hydroxytamoxifen synergistically inhibit the proliferation of breast cancer cells through activating apoptosis signaling pathway in vitro and in vivo. Chin Med. 2020; 15:23. PMC: 7063777. DOI: 10.1186/s13020-020-00305-1. View

Zhu Y, Zhong Y, Long X, Zhu Z, Zhou Y, Ye H . Deoxyshikonin isolated from inhibits colorectal cancer by down-regulating the PI3K/Akt/mTOR pathway. Pharm Biol. 2019; 57(1):412-423. PMC: 6600065. DOI: 10.1080/13880209.2019.1626447. View

Hernandez-Silva C, Villegas-Pineda J, Pereira-Suarez A . Expression and Role of the G Protein-Coupled Estrogen Receptor (GPR30/GPER) in the Development and Immune Response in Female Reproductive Cancers. Front Endocrinol (Lausanne). 2020; 11:544. PMC: 7468389. DOI: 10.3389/fendo.2020.00544. View

Jia L, Zhu Z, Li H, Li Y . Shikonin inhibits proliferation, migration, invasion and promotes apoptosis in NCI-N87 cells via inhibition of PI3K/AKT signal pathway. Artif Cells Nanomed Biotechnol. 2019; 47(1):2662-2669. DOI: 10.1080/21691401.2019.1632870. View

Pei T, Zheng C, Huang C, Chen X, Guo Z, Fu Y . Systematic understanding the mechanisms of vitiligo pathogenesis and its treatment by Qubaibabuqi formula. J Ethnopharmacol. 2016; 190:272-87. DOI: 10.1016/j.jep.2016.06.001. View

Chevalier N, Hinault C, Clavel S, Paul-Bellon R, Fenichel P . GPER and Testicular Germ Cell Cancer. Front Endocrinol (Lausanne). 2021; 11:600404. PMC: 7870790. DOI: 10.3389/fendo.2020.600404. View

10.

Shilnikova K, Piao M, Kang K, Ryu Y, Park J, Hyun Y . Shikonin induces mitochondria-mediated apoptosis and attenuates epithelial-mesenchymal transition in cisplatin-resistant human ovarian cancer cells. Oncol Lett. 2018; 15(4):5417-5424. PMC: 5858079. DOI: 10.3892/ol.2018.8065. View

11.

Fujiwara S, Terai Y, Kawaguchi H, Takai M, Yoo S, Tanaka Y . GPR30 regulates the EGFR-Akt cascade and predicts lower survival in patients with ovarian cancer. J Ovarian Res. 2012; 5(1):35. PMC: 3543193. DOI: 10.1186/1757-2215-5-35. View

12.

Boulos J, Rahama M, Hegazy M, Efferth T . Shikonin derivatives for cancer prevention and therapy. Cancer Lett. 2019; 459:248-267. DOI: 10.1016/j.canlet.2019.04.033. View

13.

Li B, Yuan Z, Jiang J, Rao Y . Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway. Biosci Rep. 2018; 38(6). PMC: 6294622. DOI: 10.1042/BSR20181693. View

14.

Zhang D, Zhao D, Liu X, Li J, Hu Y, Dou P . Effect of shikonin on the proliferation and apoptosis of human ovarian cancer cell SKOV3: A protocol of systematic review and meta-analysis. Medicine (Baltimore). 2020; 99(22):e20450. DOI: 10.1097/MD.0000000000020450. View

15.

Yang Y, Gao W, Tao S, Wang Y, Niu J, Zhao P . ER-mediated anti-tumor effects of shikonin on breast cancer. Eur J Pharmacol. 2019; 863:172667. DOI: 10.1016/j.ejphar.2019.172667. View

16.

Jiang W, Cheng Y, Zhao N, Li L, Shi Y, Zong A . Sulfated polysaccharide of Sepiella Maindroni ink inhibits the migration, invasion and matrix metalloproteinase-2 expression through suppressing EGFR-mediated p38/MAPK and PI3K/Akt/mTOR signaling pathways in SKOV-3 cells. Int J Biol Macromol. 2017; 107(Pt A):349-362. DOI: 10.1016/j.ijbiomac.2017.08.178. View

17.

Kumar A, Shashni S, Kumar P, Pant D, Singh A, Verma R . Phytochemical constituents, distributions and traditional usages of Arnebia euchroma: A review. J Ethnopharmacol. 2021; 271:113896. DOI: 10.1016/j.jep.2021.113896. View

18.

Hernandez-Silva C, Riera-Leal A, Ortiz-Lazareno P, Jave-Suarez L, Ramirez de Arellano A, Lopez-Pulido E . GPER Overexpression in Cervical Cancer Versus Premalignant Lesions: Its Activation Induces Different Forms of Cell Death. Anticancer Agents Med Chem. 2019; 19(6):783-791. DOI: 10.2174/1871520619666190206171509. View

19.

Yang B, Yang N, Chen Y, Zhu M, Lian Y, Xiong Z . An Integrated Strategy for Effective-Component Discovery of Astragali Radix in the Treatment of Lung Cancer. Front Pharmacol. 2021; 11:580978. PMC: 7898675. DOI: 10.3389/fphar.2020.580978. View

20.

Lu D, Qian J, Li W, Feng Q, Pan S, Zhang S . β-hydroxyisovaleryl-shikonin induces human cervical cancer cell apoptosis via PI3K/AKT/mTOR signaling. Oncol Lett. 2016; 10(6):3434-3442. PMC: 4665374. DOI: 10.3892/ol.2015.3769. View